Analysis of Clinicopathological Factors Influencing Survival in Patients with Renal Cell Carcinoma and Venous Tumor Thrombus.
Łukasz ZapałaSumit SharmaMichał KuncPiotr ZapałaJakub KłączPiotr KorczyńskiMichał LipowskiMichał PóźniakTomasz SuchojadTomasz DrewaMarcin MatuszewskiPiotr RadziszewskiPublished in: Journal of clinical medicine (2021)
This study aimed to define patients with renal cell cancer and coexisting tumor thrombus in order to address concerns regarding survival and prognostic factors after radical surgery. Several prognostic factors for overall survival (OS) were assessed in patients treated surgically at five institutions from 2012 to 2018. Univariate and multivariate analyses were used to determine the independent risk factors of OS. A total of 142 patients were eligible for further analysis (mean age of 64.75 years, 56% males). Most patients presented with clear cell carcinoma (95%). The Mayo stage was predominantly 0-1 (88%). Distant visceral metastases at the time of diagnosis were present in 36 patients (25%), whereas nodal metastases were present in 24 patients (16.9%). During the follow-up period (mean of 32.5 months), the 3-year OS rate reached 68.2%. The majority of patients received no adjuvant treatment (n = 107). In a multivariable model predicting OS, regional lymph node status (p < 0.001), distant metastases (p = 0.009), tumor grade (p = 0.002), duration of hospitalization (p = 0.016), and Clavien-Dindo grade (p = 0.047) were identified as independent prognostic factors. A subgroup of patients with specific clinicopathological factors may benefit most from the radical surgery, including patients without regional lymph node or distant metastases and with low tumor grades, whereas short hospitalization and low Clavien-Dindo grades represent additional independent prognostic factors.
Keyphrases
- prognostic factors
- end stage renal disease
- lymph node
- ejection fraction
- newly diagnosed
- chronic kidney disease
- risk factors
- stem cells
- randomized controlled trial
- squamous cell carcinoma
- mesenchymal stem cells
- early stage
- patient reported outcomes
- clinical trial
- metabolic syndrome
- radiation therapy
- single cell
- free survival
- coronary artery bypass